Abordaje del paciente sintomático con CECC recurrente/metastásico

Previous Page

Next Page

Page Background

EXTREME como estándar en 1ª línea de CECCR/M

Group A

Either cisplatin (100 mg/m

2

IV, d1)

or carboplatin (AUC 5, d1)

+ 5-FU (1000 mg/m

2

IV, d1–4):

3-week cycles

+ ERBITUX 400 mg/m

2

initial dose

then 250 mg/m

2

weekly

Group B

Either cisplatin (100 mg/m

2

IV, d1)

or carboplatin (AUC 5, d1)

+ 5-FU (1000 mg/m

2

IV, d1–4):

3-week cycles

No treatment

ERBITUX

Randomized

Progressive disease or unacceptable toxicity

6 chemotherapy cycles maximum

Vermorken JB et al. N Engl J Med 2008;359:1116–1127